Stock EX1 EXOPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Exopharm Limited

Equities

EX1

AU0000030975

Delayed Australian S.E.
Other stock markets
 01:10:45 02/10/2023 BST 		5-day change 1st Jan Change
0.0275 AUD +10.00% Intraday chart for Exopharm Limited -.--% -.--%
02-26 Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
2023 Exopharm to Cut CEO Role Amid Cost Reductions MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Exopharm to Cut CEO Role Amid Cost Reductions
MT
Exopharm Limited Announces Ian Dixon's Employment as CEO Expects to End in Early Calendar Year 2024
CI
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Exopharm Limited Announces Executive Changes
CI
Exopharm Achieves Initial Success With Exosome Products; Shares Fall 21%
MT
Exopharm Secures R&D Cash Loan Advance from Radium Capital
MT
Exopharm Limited announced that it has received AUD 1 million in funding
CI
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
Exopharm Limited Announces Board Changes
CI
Exopharm Limited announced that it expects to receive AUD 0.6 million in funding
CI
Exopharm Limited Announces Resignation of Elizabeth McGregor as Non-Executive Director
CI
Sartorius BIA Separations and Exopharm Ltd Testing the Synergy of Exopharm's Patented LEAP Technology Together with Bia's Unique Cim (Convective Interaction Media) Monolith Chromatography for Improved Large- Scale Exosome Production and Commercialization
CI
Exopharm Limited Will Commence LEAP Technology Transfer to AIRM under MSA
CI
Exopharm Receives $2.6 Million R&D Tax Rebate
MT
Exopharm Says Drug Product Safe After Animal Testing
MT
Exopharm Limited Announces Study Results Indicate Exosomes Safe for Clinical Pursuit
CI
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
Exopharm Limited Auditor Raises 'Going Concern' Doubt
CI
Exopharm Enters Loan Agreement for Early Access to R&D Tax Rebate
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EX1 Stock
  4. News Exopharm Limited